Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06854393 · ClinicalTrials.gov registry record · Phase 2
Lacripep for Corneal Wound Healing Study
A Phase 2 study of Corneal Epithelial Wound Healing, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
- 1
- Study location
NCT06854393 is a Phase 2 study of Corneal Epithelial Wound Healing that is actively recruiting participants, run by Henry M. Jackson Foundation for the Advancement of Military Medicine. The registered enrollment target is 88 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06854393, a Phase 2 study of Corneal Epithelial Wound Healing, is actively recruiting participants, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to evaluate the safety and effectiveness of Lacripep as a therapy for superficial corneal injury repair after Photorefractive keratectomy (PRK).
Conditions Studied
Interventions
- DRUG 0.00025% Lacripep ophthalmic solution and Placebo
Study Locations (1)
Virginia
- Alexander T. Augusta Military Medical Center - Fort Belvoir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2025-05-23 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06854393
The ClinicalTrials.gov registry entry for NCT06854393 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry M. Jackson Foundation for the Advancement of Military Medicine, which has 60 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Corneal Epithelial Wound Healing appearing as the primary indexed condition, and to 1 intervention - of which 0.00025% Lacripep ophthalmic solution and Placebo is the first listed.
NCT06854393 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT06854393 about?
NCT06854393 is a clinical study titled "Lacripep for Corneal Wound Healing Study". The objective of this study is to evaluate the safety and effectiveness of Lacripep as a therapy for superficial corneal injury repair after Photorefractive keratectomy (PRK).
What is the current status of trial NCT06854393?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2025-05-23. Estimated completion is 2027-09.
What conditions does trial NCT06854393 study?
This clinical trial studies the following conditions: Corneal Epithelial Wound Healing.
What interventions are being tested in trial NCT06854393?
The interventions under investigation include: 0.00025% Lacripep ophthalmic solution and Placebo (DRUG).
Who is sponsoring clinical trial NCT06854393?
This trial is sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine, which has 60 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06854393 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.